Methods for detecting sinusoidal obstructive syndrome (sos)
OwnerSophie PACZESNYinventor
Life of this patent
Estimating the term…
Abstract
Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.
Claims20
A diagnostic biomarker panel comprising suppressor of tumorigenicity 2 (ST2), angiopoietin 2 (ANG2), L-Ficolin, hyaluronic acid (HA) and vascular cell adhesion molecule 1 (VCAM1).
A prognosis biomarker panel comprising L-Ficolin, hyaluronic acid (HA) and vascular cell adhesion molecule 1 (VCAM1).
A method of diagnosing or of aiding diagnosis of sinusoidal obstructive syndrome (SOS) in a subject receiving hematopoietic stem cell transplantation (HSCT), the method comprising:
- measuring in a biological sample from the subject the expression of at least one biomarker selected from the group consisting of ST2, ANG2, L-Ficolin, HA, and VCAM1 by contacting the biological sample obtained from the subject with a specific binding agent that specifically binds to the biomarker, wherein the specific binding agent forms a complex with the biomarker;
- and
- detecting the agent-biomarker complex, thereby determining the biomarker expression level;
- wherein an elevated biomarker expression level compared to biomarker expression obtained from a biological sample obtained from a control is indicative of SOS.
A method of prognosing or of aiding prognosis of sinusoidal obstructive syndrome (SOS) in a subject receiving hematopoietic stem cell transplantation (HSCT), the method comprising:
- measuring in a biological sample from the subject the expression of at least one biomarker selected from the group consisting of ST2, ANG2, L-Ficolin, HA, and VCAM1 by contacting the biological sample obtained from the subject with a specific binding agent that specifically binds to the biomarker, wherein the specific binding agent forms a complex with the biomarker;
- and
- detecting the agent-biomarker complex, thereby determining the biomarker expression level;
- wherein an elevated biomarker expression level compared to biomarker expression obtained from a biological sample obtained from a control is indicative of a prognosis for a subject having SOS.
Dependencies are inferred from the claim text.